Servier Completes Acquisition of Agios Pharmaceuticals’ Oncology Enterprise

PARIS and BOSTON, April 1, 2021 /PRNewswire/ — Servier, a world pharmaceutical organization, right now declared that it has successfully done its acquisition of Agios Pharmaceuticals’ commercial, medical, and investigate-stage oncology portfolio for up to $2 billion furthermore royalties. The acquisition instantly strengthens Servier’s industrial existence in the U.S. malignant hematology market and presents the prospective for extended-expression progress into the solid tumor place.

“We are happy to welcome an exceptionally gifted crew that will make it possible for us to reinforce our strategic concentrate in oncology and expand our scientific abilities in cellular metabolic process,” claimed Olivier Laureau, President of Servier. “It is an important milestone in Servier’s oncology tactic as it considerably reinforces the Group’s presence in the U.S. Collectively, with this expanded crew, we continue to be fully commited to addressing the unmet requires of patients residing with cancer throughout the world.”

“We respect the support of our staff members, associates and Agios crew in making certain a seamless integration,” stated David K. Lee, CEO, Servier Prescription drugs. “The addition of TIBSOVO® and IDHIFA® to our pipeline makes it possible for us to develop our oncology leadership capabilities in the U.S. and speed up scientific advancements for clients with hematological malignancies, together with acute myeloid leukemia.”

As part of the transaction, U.S.-primarily based Agios workers who principally guidance the oncology enterprise will be part of Servier Prescribed drugs LLC, a U.S. subsidiary of Servier. The transaction involves the transfer to Servier of Agios Pharmaceuticals’ oncology portfolio, improvement pipeline and investigation applications, notably:

  • TIBSOVO (ivosidenib tablets), which is accredited in the U.S. as monotherapy for the therapy of grownups with IDH1-mutant relapsed or refractory acute myeloid leukemia (AML) and for older people with recently diagnosed IDH1-mutant AML who are ≥75 a long time old or who have comorbidities that preclude the use of intensive induction chemotherapy. TIBSOVO is also under investigation in two Phase 3 mixture trials in newly identified AML, and as a prospective treatment for IDH1-mutant myelodysplastic syndrome (MDS). Also, previous thirty day period, a supplemental new drug application (sNDA) has been submitted to the Food and drug administration for TIBSOVO as a potential therapeutic option for sufferers with beforehand taken care of, IDH1-mutated cholangiocarcinoma (bile duct most cancers) in the U.S. A precedence critique was asked for for the application, which, if granted, could result in a 6-month overview procedure.
  • IDHIFA (enasidenib)*, a medication co-promoted with Bristol Myers Squibb in the U.S. wherever it is authorised for the treatment of grownup people with relapsed or refractory AML with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an Food and drug administration-authorized test.
  • Vorasidenib, an investigational, brain-penetrant, dual inhibitor of mutant IDH1 and IDH2 which is currently currently being analyzed in the registration-enabling Phase 3 INDIGO review in patients with IDH-mutant low-grade glioma.
  • AG-270, an investigational initially-in-class methionine adenosyltransferase 2a (MAT2A) inhibitor currently being evaluated in mixture with taxanes in patients with methylthioadenosine phosphorylase (MTAP)-deleted non-modest cell lung cancer and pancreatic most cancers.

Below the terms of the transaction settlement, Agios acquired an upfront payment of $1.8 billion from Servier and is qualified to obtain an extra $200 million in a prospective regulatory milestone, plus royalties. The transaction has been approved by both equally companies’ respective boards of administrators and Agios’ shareholders. All regulatory clearances have been acquired from federal government authorities outlined in the arrangement.

About Servier Group
Servier is a worldwide pharmaceutical group governed by a Foundation. With a powerful intercontinental existence in 150 international locations and a complete income of 4.7 billion euros in 2020, Servier employs 22,500 people throughout the world. Servier is an independent team that invests over 20{f13b67734a7459ff15bce07f17c500e58f5449212eae0f7769c5b6fbcf4cc0c4} of its manufacturer-title earnings in Exploration and Development each year. To speed up therapeutic innovation for the advantage of individuals, the Group is committed to open up and collaborative innovation with educational associates, pharmaceutical teams, and biotech organizations. It also integrates the patient’s voice at the heart of its routines, from research to assistance beyond the pill.

A leader in cardiology, the ambition of the Servier Group is to turn into a recognized and ground breaking participant in oncology. Its progress is based on a sustained motivation to cardiovascular and metabolic diseases, oncology and immuno-inflammatory, and neurodegenerative conditions. To advertise access to healthcare for all, the Servier Group also delivers a assortment of good quality generic drugs masking most pathologies.

A lot more facts:

Follow us on social media: LinkedIn, Fb, Twitter

About Servier Prescription drugs
Servier Pharmaceuticals, LLC is a professional-stage business with a passion for innovation and increasing the life of people, their households and caregivers. A privately held business, Servier has the exclusive independence to devote its time and electricity toward putting people who call for our cure and care initial, with foreseeable future expansion pushed by innovation in places of unmet health care will need.

Servier is committed to finding methods that will tackle today’s challenges. The company’s oncology portfolio of progressive medications is intended to deliver a lot more daily life-preserving treatment options to a bigger variety of patients, across the complete spectrum of disorder and in a wide variety of tumor forms.

Servier believes co-development is essential to driving innovation and is actively creating alliances, acquisitions, licensing bargains and partnerships that bring remedies and accelerate obtain to therapies. With our business skills, international access, scientific abilities and commitment to medical excellence, Servier Prescribed drugs is dedicated to bringing the assure of tomorrow to the people that we serve.

More details:

Adhere to us on social media: LinkedIn, Twitter

Push Contacts

Servier Team (France and globally)
Sonia Marques
[email protected]
+33 ()1 55 72 40 21 / + 33 ()7 84 28 76 13

Servier Prescription drugs (U.S.)
Kelly Schlemm
[email protected]

This launch contains typical info about the Servier Team and its entities (hereinafter “Servier and its Affiliates”) and is meant for informational uses only. The information is believed to be reliable on the other hand, Servier and its Affiliate marketers make no representation as to the accuracy or completeness of the information contained herein or usually offered and settle for no duty or liability, in contract, in tort, in negligence, or if not, really should the details be located to be inaccurate or incomplete in any respect.

Servier and its Affiliate marketers are not acting as an advisor to the receiver of this details, and the supreme choice to move forward with any transaction rests solely with the receiver of this data. Consequently, prior to coming into into any proposed transaction, the recipient of this facts ought to figure out, without having reliance upon Servier or its Affiliates, the economic threats and deserves, as nicely as the legal, tax, and accounting characterizations and repercussions, of the transaction and that it is able to believe these threats.

This assertion also includes ahead-wanting statements that are issue to various degrees of uncertainty and hazard. Investigational new drugs and indications are matter to further scientific and medical overview and regulatory approval. They are not accredited for use by the Fda.

Any reliance placed on this doc is completed totally at the chance of the human being inserting these kinds of reliance. The details contained in this doc is neither an give to sell nor the solicitation of an present to enter into a transaction.

The content material of this doc is a summary only, is not complete, and does not consist of all materials information about Servier and its Affiliates, together with potential conflicts of fascination.

To the maximum extent permitted by relevant legal guidelines and polices, Servier and its Affiliate marketers disclaim all representations, warranties, situations and assures, regardless of whether express, implied, statutory or of other type, nor does it take any duty to any individual, in connection with this doc. Devoid of prejudice to the generality of the foregoing, Servier and its Affiliates do not warrant or represent that the details or opinions contained in this document is correct or complete.

To the maximum extent permitted by applicable legal guidelines and restrictions, Servier and its Affiliates shall not be liable for any reduction, harm or expenditure by any means, no matter if direct or oblique, howsoever arising, no matter whether in contract, tort (like carelessness), rigorous legal responsibility or if not, for direct, indirect, incidental, consequential, punitive or exclusive damages arising out of or in relationship with this document, which includes (without having limitation) any system of motion taken on the basis of the similar.

The estimates, methods, and sights expressed in this doc are dependent upon earlier or present knowledge and information and facts and are issue to change with out discover.

*You should see the whole prescribing details for IDHIFA (enasidenib) and TIBSOVO (ivosidenib), which include the Boxed WARNINGS.

Check out first content to download multimedia: drugs-oncology-enterprise-301259960.html

Resource Servier Prescription drugs